Table 5.

Side effects and problems from NPS use per country and per lifetime use

	Acute unpleasant side effects		Mid- or long-term problems		Social problems
Country
Germany	62.2%	.000	26.9%	.000	22.9%	.000
Hungary	78.7%		63.7%		60.4%
Ireland	95.2%		70.5%		74.6%
The Netherlands	35.7%		24.7%		9.5%
Poland	78.5%		49.3%		47.2%
Portugal	42.2%		15.5%		15.2%
Life time use
Herbal blends and/or pure synthetic cannabinoids	69.7%		42.6%		38.6%
Branded and/or pure stimulants	56.4%		37.2%		28.8%
Psychedelics	56.8%		30.9%		25.6%
Dissociatives	72.1%		44.5%		39.8%
Other NPS	61.0%		39.4%		34.4%